Year: 2023
Type: conference-abstract
Abstract: AIM The goal of this study was to understand sex-specific differences in the molecular, clinical and radiological tumor parameters and survival outcomes of Glioblastoma (GBM) patients within the international GBM dataset, known as the ReSPOND (Radiomic Signatures for PrecisiON Diagnostics) consortium. METHODS Sex-based differences were retrospectively studied in 1922 GBM patients from the ReSPOND consortium which includes information from over 14 institutions across 3 continents. The parameters include age, Methylguanine-DNA Methyltransferase (MGMT) promoter methylation status, isocitrate dehydrogenase 1 (IDH1) mutation status, Karnofsky performance status (KPS), extent of resection (EOR), tumor epicenter, volumes, laterality and spatial extent. Non-parametric tests, log-rank test and cox-proportional hazard analysis were performed to understand sex-based differences in tumor parameters, survival rates and hazard ratios. Spatial atlases were generated to understand radiological parameters such as tumor spatial extent. RESULTS GBM in was diagnosed at a median age of 62.6 years in females compared to 61 years in males (p = 0.001). Additionally, 44% females compared to 37% males (p = 0.04) had methylated MGMT and 79% females compared to 73% males (p = 0.004) had IDH1 wildtype. The tumor volumes were smaller in females (necrotic core, edema, and enhancing tumor) compared to males. Females exhibited a higher prevalence of right hemisphere (39.6%) and right temporal lobe tumors (19.7%), while males showed a higher prevalence of left hemisphere (40.3%) left temporal lobe tumors (23.7%). No significant sex-based differences in OS and PFS was observed in overall sample, although longer PFS was observed in elderly (above 60 years) female patients. CONCLUSION This is a first international large cohort study looking at sex-based differences in GBM patients using the ReSPOND consortium data. Several sex-specific differences in the distribution of various tumor phenotypes were noted, however sex was not a contributing factor in OS and PFS.
Source: Neuro-Oncology
Authors: Sree Gongala, Jose Garcia, Nisha Korakavi, Nirav Patil, Hamed Akbari, Charit Tippareddy, Andrew Sloan, Jill Barnholtz-Sloan, Spyridon Bakas, Anahita Fathi Kazerooni, Chiharu Sako, Ujjwal Baid, Steven Brem, Robert A Lustig, Jaume Capellades, MacLean Nasrallah, Donald M O'Rourke, Pamela LaMontagne, Daniel S Marcus, Carmen Balana, Josep Puig, Kristin Waite, Rivka Colen, Yoon Seong Choi, Seung-Koo Lee, Adam P Dicker, Adam E Flanders, Wenyin Shi, Brent Griffith, Laila M Poisson, Lisa R Rogers, Thomas C Booth, Rajan Jain, Arnab Chakravarti, Joshua Palmer, Suyash Mohan, Pallavi Tiwari, Mariam Aboian, Sung Soo Ahn, Christos Davatzikos, Chaitra Badve
Institutions: University Hospitals Seidman Cancer Center, University of Pennsylvania, University Hospitals of Cleveland, Case Western Reserve University, Piedmont Atlanta Hospital, National Cancer Institute, Parc de Salut, Institut Català d'Oncologia, University of Pittsburgh, National University of Singapore, Yonsei University Health System, Thomas Jefferson University, Sidney Kimmel Cancer Center, Henry Ford Health, King's College London, NYU Langone Health, The Ohio State University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, University of Wisconsin–Madison, Yale University, Yonsei University
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4388588558